PainReform (PRFX)
NASDAQ:PRFX
Top Page
PainReform
(NASDAQ:PRFX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.66
▼(-17.63% Downside)
Action:ReiteratedDate:01/24/26
The score is weighed down primarily by weak financial performance (minimal revenue, widening losses, and rising cash burn alongside shrinking equity). Technicals also remain bearish with the stock trading below key moving averages, while valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.
Positive Factors
Diversified business model
The company formally repositioned from a single-asset pain-treatment developer to a combined healthcare and clean-energy technology platform. That strategic diversification reduces single-product concentration risk and opens multiple addressable markets, supporting more durable growth pathways over the next several quarters.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow creates ongoing financing needs. Continued cash burn constrains runway, forces reliance on external funding, and can drive dilution or delay development/commercial milestones if capital access is constrained over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
The company formally repositioned from a single-asset pain-treatment developer to a combined healthcare and clean-energy technology platform. That strategic diversification reduces single-product concentration risk and opens multiple addressable markets, supporting more durable growth pathways over the next several quarters.
Read all positive factors
PainReform (PRFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.74M
Dividend YieldN/A
Average Volume (3M)186.11K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding783,068
10 Day Avg. Volume213,091
30 Day Avg. Volume186,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap-1.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-176.4
Revenue Forecast (FY)$10.31M
PainReform Business Overview & Revenue Model
Company Description
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-bas...
How the Company Makes Money
PainReform generates revenue primarily through the development and potential commercialization of its proprietary drug formulations. The company's revenue model is centered around advancing its flagship product, PRF-110, through clinical trials an...
PainReform Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 86.00K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -16.00K | -15.00K | 71.00K | ― | 0.00 |
| EBITDA | -3.94M | -14.55M | -9.57M | -8.76M | -7.20M | -1.67M |
| Net Income | -4.09M | -14.59M | -9.34M | -8.79M | -7.25M | -4.05M |
Balance Sheet | ||||||
| Total Assets | 11.16M | 4.53M | 9.93M | 12.33M | 19.07M | 17.80M |
| Cash, Cash Equivalents and Short-Term Investments | 3.48M | 4.26M | 8.03M | 4.10M | 16.54M | 15.68M |
| Total Debt | 56.00K | 45.00K | 86.00K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.72M | 2.70M | 2.69M | 1.31M | 991.00K | 1.18M |
| Stockholders Equity | 8.44M | 1.82M | 7.24M | 11.02M | 18.08M | 16.62M |
Cash Flow | ||||||
| Free Cash Flow | -5.96M | -12.63M | -6.69M | -6.46M | -6.60M | -2.57M |
| Operating Cash Flow | -5.96M | -12.62M | -6.68M | -6.46M | -6.55M | -2.56M |
| Investing Cash Flow | -51.00K | -13.00K | 5.99M | -6.01M | -50.00K | -10.00K |
| Financing Cash Flow | 6.70M | 8.86M | 4.62M | 0.00 | 7.48M | 17.31M |
PainReform Technical Analysis
Negative
0.80
Price Trends
3.23
Negative
3.92
Negative
5.63
Negative
Market Momentum
-0.27
Positive
30.27
Neutral
12.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRFX, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 2.67, below the 50-day MA of 3.23, and below the 200-day MA of 5.63, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 30.27 is Neutral, neither overbought nor oversold. The STOCH value of 12.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRFX.
PainReform Risk Analysis
PainReform disclosed 46 risk factors in its most recent earnings report. PainReform reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PainReform Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.53M | -0.42 | ― | ― | ― | ― | |
44 Neutral | $1.74M | -0.13 | ― | ― | ― | ― | |
42 Neutral | $3.21M | -2.90 | -43.00% | ― | -26.92% | 69.90% | |
40 Underperform | $12.78M | -1.59 | -63.82% | ― | ― | ― | |
| ― | $5.01M | -0.84 | -9999.00% | ― | ― | 79.31% |
* Healthcare Sector Average
PRFX
PainReform
2.22
-10.18
-82.10%
CPHI
China Pharma Holdings
0.64
-2.00
-75.80%
RDHL
RedHill Biopharma
0.89
-1.86
-67.67%
COSM
Cosmos Holdings
0.34
-0.14
-29.69%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.90
-9.20
-91.13%
PainReform Corporate Events
PRF Technologies Announces 1-for-5 Reverse Share Split Effective February 6, 2026
Feb 3, 2026
On February 3, 2026, PRF Technologies Ltd. announced it will implement a 1-for-5 reverse share split of its ordinary shares, effective for trading on the Nasdaq Capital Market starting Friday, February 6, 2026. The move will consolidate every five...
PRF Technologies Files First Patent for AI-Driven Solar Micro-Climate Forecasting
Jan 20, 2026
On January 20, 2026, PRF Technologies announced it had filed its first patent application for proprietary micro-climate modeling methods designed to significantly enhance the accuracy of power production forecasts at individual solar plants. The f...
PainReform Rebrands as PRF Technologies to Reflect Expansion into Healthcare and AI-Driven Energy
Jan 15, 2026
On January 15, 2026, PainReform Ltd. announced it had changed its corporate name to PRF Technologies Ltd., following shareholder approval at the company’s January 6, 2026 annual general meeting, in a move designed to signal its evolution bey...
PainReform Reports Positive Phase I Safety Data for OcuRing-K Ocular Drug Platform
Jan 12, 2026
On January 12, 2026, PainReform and its majority-owned subsidiary LayerBio reported that their OcuRing™-K drop-less, sustained-release intraocular drug delivery platform for cataract surgery demonstrated a favorable safety profile in a serie...
PainReform Files Pro Forma Financials Following Majority Acquisition of LayerBio
Jan 7, 2026
On January 7, 2026, PainReform Ltd. filed a Form 6-K in the United States providing updated financial disclosure related to its acquisition of LayerBio Inc., a transaction first announced in July 2025 and completed on August 13, 2025, in which Pai...
PainReform Shareholders Approve All Proposals at Adjourned 2026 Annual Meeting
Jan 6, 2026
On January 6, 2026, PainReform Ltd. held its Adjourned Annual General Meeting of Shareholders, at which investors approved all six proposals presented, each receiving the required majority vote. The approvals, following an earlier notice and proxy...
PainReform’s DeepSolar Unveils Smart TDD to Speed and Sharpen Solar Asset Due Diligence
Jan 5, 2026
On January 5, 2026, PainReform announced that its DeepSolar business unit launched Smart TDD, a next-generation solar technical due diligence service designed to deliver faster, more accurate, and more comprehensive audits of solar asset performan...
PainReform Adjourns Annual Shareholder Meeting Due to Lack of Quorum
Dec 30, 2025
On December 30, 2025, PainReform Ltd. convened its Annual General Meeting of Shareholders in Tel Aviv but was unable to proceed with the meeting’s agenda due to a lack of quorum. As a result, the company adjourned the meeting for one week an...
PainReform’s LayerBio Platform Advances with Multi-Drug Capability
Dec 10, 2025
On December 10, 2025, PainReform Ltd. announced the successful RD assessment of its LayerBio drop-less, sustained-release ocular platform, confirming its ability to incorporate multiple drug entities. This development supports the platform’s...
PainReform Initiates Phase II Development for OcuRing™-K
Dec 2, 2025
On December 2, 2025, PainReform Ltd. announced the commencement of its development plan for OcuRing™-K, a sustained-release ocular therapy designed for post-cataract surgery pain and inflammation management. This initiative marks a significa...
PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals
Nov 25, 2025
On November 25, 2025, PainReform Ltd. announced its upcoming Annual General Meeting of Shareholders scheduled for December 30, 2025, in Tel Aviv, Israel. The meeting’s agenda includes significant proposals such as the re-election of Dr. Ehud...
PainReform’s DeepSolar Advances AI Reporting Engine for Solar Assets
Nov 12, 2025
On November 12, 2025, PainReform Ltd. announced that its solar energy unit, DeepSolar, has made significant progress in developing an AI-driven automated reporting engine for solar-asset analysis. This new engine is designed to streamline the proc...
PainReform’s DeepSolar Advances with NVIDIA Connect and Pilot Projects
Nov 5, 2025
On November 5, 2025, PainReform Ltd. announced that its solar energy unit, DeepSolar, was featured in a Watchlist Interview by The Market Link, highlighting its participation in the NVIDIA Connect program. The interview emphasized DeepSolar’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.